- NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
- NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors
- NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark Office
- NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June
- NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings
- NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
- NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024
- NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
- NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
More ▼
Key statistics
As of last trade NewAmsterdam Pharma Company NV (KH6:STU) traded at 17.00, -24.11% below its 52-week high of 22.40, set on Jan 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 17.00 |
---|---|
High | 17.00 |
Low | 17.00 |
Bid | 17.10 |
Offer | 17.70 |
Previous close | 16.80 |
Average volume | 0.00 |
---|---|
Shares outstanding | 89.98m |
Free float | 84.84m |
P/E (TTM) | -- |
Market cap | 1.69bn USD |
EPS (TTM) | -2.70 USD |
Data delayed at least 15 minutes, as of Jul 22 2024.
More ▼